Ruxolitinib Resolves Severe Diarrhea Following BCMA-Targeted CAR T-Cell Therapy

Managing Intractable Enterocolitis in BCMA-Targeted Therapy

The treatment of relapsed or refractory multiple myeloma has been significantly altered by the introduction of chimeric antigen receptor (CAR) T-cell therapies, which genetically engineer a patient's own immune cells to recognize and destroy malignant plasma cells [1]. Despite their efficacy, these treatments are frequently complicated by systemic toxicities, most notably cytokine release syndrome (a systemic inflammatory response) and neurotoxicity [2, 3]. Recently, clinicians have identified a distinct and severe complication known as immune effector cell-associated enterocolitis, characterized by profound, watery diarrhea that often resists standard management [4]. This condition frequently results in extreme weight loss, a requirement for total parenteral nutrition (intravenous feeding), and high mortality rates [4]. Because this syndrome often fails to respond to conventional corticosteroids, there is an urgent clinical need for targeted immunosuppressive strategies [3, 4]. A recent study investigates a specific pharmacological approach to resolve this life-threatening gastrointestinal toxicity.

High Mortality and Therapeutic Rationale

Intractable diarrhea has emerged as a life-threatening complication following B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapy for patients with multiple myeloma. This gastrointestinal toxicity is characterized by its resistance to standard interventions, and clinical data indicate that reported mortality rates for BCMA CAR T-cell-associated intractable diarrhea range from 36% to 50%. Because this is a newly recognized phenomenon, the optimal clinical management is currently unknown, leaving clinicians with few established protocols to address the rapid decline of these patients. In an effort to identify a targeted intervention, researchers hypothesized that ruxolitinib might serve as an effective therapy. Ruxolitinib is a Janus kinase (JAK) inhibitor, a class of medication that interferes with the signaling pathways responsible for the production of inflammatory cytokines. This hypothesis was primarily informed by the established success of ruxolitinib in treating graft-versus-host disease (a condition where donor immune cells attack the recipient's tissues) following allogeneic bone marrow transplant. Furthermore, the researchers drew upon the documented efficacy of ruxolitinib in managing other immune-driven diarrhea syndromes. By modulating aberrant immune responses, the drug could potentially calm the specific inflammatory environment created by BCMA-targeted CAR T-cell therapy, offering a much-needed rescue strategy for patients failing supportive care.

Clinical and Histopathologic Response to JAK Inhibition

The researchers documented a series of 5 patients who presented with severe diarrhea following BCMA-targeted CAR T-cell treatment for multiple myeloma. Within this cohort, three patients received ruxolitinib as a targeted intervention for their gastrointestinal symptoms. The clinical response was uniform among those treated; all three patients experienced rapid clinical improvement in their diarrheal symptoms. This suggests that the Janus kinase inhibition provided by ruxolitinib can effectively interrupt the inflammatory cascade responsible for the intractable bowel movements seen in this patient population, potentially preventing the need for prolonged intravenous feeding or intensive care admissions. To confirm the clinical observations with objective data, the researchers utilized matched pretreatment and posttreatment biopsies in two patients from the series. These tissue samples allowed for a direct comparison of the gastrointestinal mucosa before and after the administration of ruxolitinib. Both patients with matched biopsies showed signs of histopathologic response, defined as the visible improvement in tissue samples under a microscope, including a reduction in inflammatory markers and cellular damage. Notably, one of these patients with a confirmed histopathologic response was diagnosed with CAR T-cell-associated indolent T-cell lymphoproliferative disease of the gastrointestinal tract, a condition characterized by a slow-growing accumulation of T-cells within the gut wall. The resolution of symptoms and the improvement in tissue architecture in this specific case provide evidence that ruxolitinib may address even complex, proliferative immune complications arising from CAR T-cell therapy. For practicing oncologists and gastroenterologists, these findings highlight a highly actionable treatment pathway for a previously unmanageable and frequently fatal complication of modern myeloma therapy.

References

1. Zhou X, Rasche L, Kortüm KM, Danhof S, Hudecek M, Einsele H. Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies. Frontiers in Immunology. 2020. doi:10.3389/fimmu.2020.620312

2. Fergusson N, Adeel K, Kekre N, Atkins H, Hay KA. A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells. Frontiers in Immunology. 2023. doi:10.3389/fimmu.2023.1178403

3. Thompson JA, Schneider BJ, Brahmer JR, et al. Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2022. doi:10.6004/jnccn.2022.0020

4. Blumenberg V, Birocchi F, Shih AR, et al. Ruxolitinib for refractory immune effector cell enterocolitis following ciltacabtagene autoleucel CAR T-cell therapy for multiple myeloma. Blood. 2025. doi:10.1182/blood-2025-2392